A telltale boost of activity at the back of the brain while processing emotional information predicted whether depressed patients would respond to an experimental rapid-acting antidepressant, a National Institutes of Health study has found.
"We have discovered a potential neuroimaging biomarker that may eventually help to personalize treatment selection by revealing brain-based differences between patients," explained Maura Furey, Ph.D., of NIH's National Institute of Mental Health (NIMH).
Furey, NIMH's Carlos Zarate, M.D., and colleagues, reported on their functional magnetic resonance imaging (fMRI) study of a pre-treatment biomarker for the antidepressant response to scopolamine (http://www.nimh.nih.gov/science-news/2006/nimh-researchers-discover-medications-antidepressant-potential.shtml), Jan. 30, 2013, online in JAMA Psychiatry.
Scopolamine, better known as a treatment for motion sickness, has been under study (http://projectreporter.nih.gov/project_info_description.cfm?aid=8556944&icde=15145736&ddparam=&ddvalue=&ddsub=&cr=2&csb=default&cs=ASC) since Furey and colleagues discovered its fast-acting antidepressant properties in 2006.
Unlike ketamine (http://www.nimh.nih.gov/science-news/2012/brain-signal-ids-responders-to-fast-acting-antidepressant.shtml), scopolamine works through the brain's acetylcholine chemical messenger system.
The NIMH team's research has demonstrated that by blocking receptors for acetylcholine on neurons, scopolamine can lift depression in many patients within a few days; conventional antidepressants typically take weeks to work. But not all patients respond, spurring interest in a predictive biomarker.
The acetylcholine system plays a pivotal role in working memory, holding information in mind temporarily, but appears to act by influencing the processing of information rather than through memory.
Imaging studies suggest that visual working memory performance can be enhanced by modulating acetylcholine-induced activity in the brain's visual processing area, called the visual cortex, when processing information that is important to the task.
Since working memory performance can predict response to conventional antidepressants and ketamine, Furey and colleagues turned to a working memory task and imaging visual cortex activity as potential tools to identify a biomarker for scopolamine response.
Depressed patients have a well-known tendency to process and remember negative emotional information. The researchers propose that this bias stems from dysregulated acetylcholine systems in some patients.
They reasoned that such patients would show aberrant visual cortex activity in response to negative emotional features of a working memory task. They also expected to find that patients with more dysfunctional acetylcholine systems would respond better to scopolamine treatment.
Before receiving scopolamine, participants performed a working memory task while their brain activity was monitored via fMRI. For some trials, it required that they pay attention to, and remember, the emotional expression (sad, happy, etc.) of faces flashing on a computer monitor.
For other trials, they had to pay attention to only the identity, or non-emotional feature, of the faces. After scanning, and over the following several weeks, 15 patients with depression and 21 healthy participants randomly received infusions of a placebo (salt solution) and/or scopolamine. Mood changes were monitored with depression rating scales.
Overall, scopolamine treatment reduced depression symptoms by 63 percent, with 11 of the patients showing a significant clinical response.
The strength of this response correlated significantly with visual cortex activity during key phases of the working memory task - while participants were paying attention to the emotional content of the faces. There was no such correlation for trials when they attended to the identity of the faces.
The findings suggest that acetylcholine system activity drives visual cortex activity that predicts treatment response - and that differences seen between depressed patients and controls may be traceable to acetylcholine dysfunction.
Overall, patients showed lower visual cortex activity than controls during the emotion phase of the task. Patients showing activity levels most dissimilar to controls experienced the greatest antidepressant response to scopolamine treatment.
Visual cortex activity in patients who didn't respond to scopolamine more closely resembled that of controls. As hypothesized, the pretreatment level of visual cortex activity appears to reflect the extent of patients' acetylcholine system dysfunction and to predict their response to the experimental medication, say the researchers.
Preliminary evidence suggests that such visual cortex activity in response to emotional stimuli may also apply to other treatments and may prove to be a shared biomarker of rapid antidepressant response, according to Furey.
The mission of the NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure.